Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111936-9a9b8c46",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H1\",\n      \"title\": \"TREM2-Dependent Microglial Metabolic Reprogramming as Primary Neuroprotective Mechanism\",\n      \"composite_score\": 0.71,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.75,\n        \"evidence_strength\": 0.72,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.70,\n        \"therapeutic_potential\": 0.80,\n        \"druggability\": 0.85,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.80,\n        \"reproducibility\": 0.75\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Human coding variants in TREM2 (R47H) increase AD risk ~3-fold, establishing TREM2 as causal\", \"pmid\": \"30327531\"},\n        {\"claim\": \"TREM2-deficient microglia fail to upregulate lipid metabolism genes and show impaired amyloid compaction\", \"pmid\": \"31278165\"},\n        {\"claim\": \"TREM2+ microglia show trajectory from homeostatic to disease-associated state in early Braak stages\", \"pmid\": \"SEA-AD snRNA-seq\"},\n        {\"claim\": \"Single-cell SLEAP analysis shows enrichment for OXPHOS gene modules preceding lysosomal genes\", \"pmid\": \"SEA-AD GSEA\"},\n        {\"claim\": \"AL002 TREM2 agonist in Phase 2 (INVOKE-2) with Denali BBB shuttle technology\", \"pmid\": \"NCT04592874\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TREM2 deficiency reduced tau-mediated neuronal loss in advanced pathology models, suggesting context-dependent role\", \"pmid\": \"31881164\"},\n        {\"claim\": \"TREM2 signaling in some contexts promotes glycolysis for inflammatory responses, not OXPHOS\", \"pmid\": \"32349664\"},\n        {\"claim\": \"Pseudotime trajectory cannot distinguish causal from correlated expression changes\", \"pmid\": \"computational limitation\"},\n        {\"claim\": \"Metabolic reprogramming interpretation ambiguous - OXPHOS could represent compensation rather than proactive protection\", \"pmid\": \"theoretical\"}\n      ],\n      \"synthesis_notes\": \"TREM2 remains strongest candidate despite skeptic's valid concerns about stage-dependency. AL002 Phase 2 data will be critical discriminator. Recommended focus on early-stage patient stratification.\"\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H3\",\n      \"title\": \"C9orf72 Haploinsufficiency Disrupts Microglial-Lymphocyte Cross-Talk\",\n      \"composite_score\": 0.64,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0",
  "tokens_used": "622",
  "persona_id": "persona-synthesizer"
}